SCHEDULE: TD Bank Discloses 4.9% Stake in UroGen Pharma
Beneficial Ownership Report
The Toronto-Dominion Bank has reported a 4.9% beneficial ownership stake in UroGen Pharma Ltd., holding over 2.3 million ordinary shares.
Summary
- The Toronto-Dominion Bank (TD Bank) has filed an Amendment No. 1 to Schedule 13G, disclosing its beneficial ownership in UroGen Pharma Ltd.
- TD Bank beneficially owns 2,302,334 ordinary shares of UroGen Pharma Ltd., representing 4.9% of the company's class of securities.
- The shares are held with sole voting power and sole dispositive power by TD Bank.
- The filing certifies that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a moderately positive development, as it indicates a significant institutional investor holds a substantial stake in UroGen Pharma Ltd., suggesting a level of confidence in the company's prospects.
Positives
- A major financial institution, The Toronto-Dominion Bank, holds a significant stake, indicating institutional interest in UroGen Pharma Ltd.
Negatives
- NA
Risks
- NA
Future Outlook
NA
Industry Context
StockSavvy.ai notes that institutional ownership disclosures, such as this Schedule 13G filing by a major bank like TD, often signal a degree of confidence or strategic interest in the underlying company within its sector. While a 4.9% stake is below the 5% threshold that typically triggers more active disclosure (Schedule 13D), it still represents a notable position for a financial institution in the pharmaceutical industry.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional holder like TD Bank may be viewed positively, potentially increasing investor confidence and liquidity.
- Company Management: Awareness of a large institutional holder can influence strategic decisions and communication with the investment community.
Key Dates
| Date | Description |
|---|---|
| 12/31/2025 | Date of event which requires the filing of this statement (reporting period end date). |
| 02/13/2026 | Date the Schedule 13G statement was signed by The Toronto-Dominion Bank. |
Keywords
UroGen Pharma Ltd., The Toronto-Dominion Bank, TD Bank, Schedule 13G, Beneficial Ownership, Ordinary Shares, Institutional Investment, M96088105
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.